PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Follicular Thyroid Cancer
- Hurthle Cell Thyroid Neoplasia
- Hurthle Cell Tumor
- Papillary Thyroid Cancer
- Poorly Differentiated Thyroid Gland Carcinoma
- Thyroid Cancer
- Thyroid Cancer, Follicular
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04544111
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Alan L Ho, MD, PhD Memorial Sloan Kettering Cancer Center
Get Well Soon